Oric Pharmaceuticals reports Q2 EPS (45c), consensus (41c)
PremiumThe FlyOric Pharmaceuticals reports Q2 EPS (45c), consensus (41c)
1M ago
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
Premium
Press Releases
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
1M ago
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
Premium
Press Releases
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
2M ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3M ago
Oric Pharmaceuticals participates in a conference call with JPMorgan
Premium
The Fly
Oric Pharmaceuticals participates in a conference call with JPMorgan
3M ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3M ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
5M ago
Oric Pharmaceuticals participates in a conference call with JPMorgan
Premium
The Fly
Oric Pharmaceuticals participates in a conference call with JPMorgan
5M ago
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Premium
Press Releases
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100